Manganese in PET imaging: Opportunities and challenges

Marie Brandt; Jens Cardinale; Ivo Rausch; Thomas L Mindt

doi:10.1002/jlcr.3754

Manganese in PET imaging: Opportunities and challenges

J Labelled Comp Radiopharm. 2019 Jun 30;62(8):541-551. doi: 10.1002/jlcr.3754.

Authors

Marie Brandt^{1

2}, Jens Cardinale^{1

2}, Ivo Rausch³, Thomas L Mindt^{1

2

4}

Affiliations

¹ Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Vienna, Austria.
² Department of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
³ Center for Medical Physics and Biomedical Engineering, Medical University Vienna, Vienna, Austria.
⁴ Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.

Abstract

Several radionuclides of the transition metal manganese are known and accessible. Three of them, ⁵¹ Mn, ^52m Mn, and ^52g Mn, are positron emitters that are potentially interesting for positron emission tomography (PET) applications and, thus, have caught the interest of the radiochemical/radiopharmaceutical and nuclear medicine communities. This mini-review provides an overview of the production routes and physical properties of these radionuclides. For medical imaging, the focus is on the longer-living ^52g Mn and its application for the radiolabelling of molecules and other entities exhibiting long biological half-lives, the imaging of manganese-dependent biological processes, and the development of bimodal PET/magnetic resonance imaging (MRI) probes in combination with paramagnetic ^nat Mn as a contrast agent.

Keywords: PET/MRI; cell labelling; immunoPET; manganese-52g; radiolabelled liposomes.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Humans
Insulin-Secreting Cells / cytology
Magnetic Resonance Imaging
Manganese*
Positron-Emission Tomography / methods*
Radioisotopes

Substances

Radioisotopes
Manganese